Another Opdivo setback for Bristol, this time on the combo front, widening Merck’s immuno-oncology lead – FiercePharma | International News Live Blog

https://internationalnewsliveblog.wordpress.com/2017/01/20/another-opdivo-setback-for-bristol-this-time-on-the-combo-front-widening-mercks-immuno-oncology-lead-fiercepharma/

FiercePharmaAnother Opdivo setback for Bristol, this time on the combo front, widening Merck's immuno-oncology leadFiercePharmaBristol-Myers won't be pursuing an accelerated first-line lung-cancer filing for its Opdivo-Yervoy combo, it said on Thursday. Share Facebook Twitter LinkedIn Email Print. So much for Bristol-Myers Squibb … http://internationalnewslive.com/another-opdivo-setback-for-bristol-this-time-on-the-combo-front-widening-mercks-immuno-oncology-lead-fiercepharma/